逸飛激光(688646.SH):2020年至2022年已累計向寧德時代等行業知名客户交付31條圓柱全極耳電芯自動裝配線及多台圓柱全極耳電芯裝配專機
格隆匯9月19日丨逸飛激光(688646.SH)在2023 年半年度業績説明會上表示,圓柱全極耳電池製造的技術難點主要在全極耳成型、集流盤焊接、入殼合蓋以及電芯封口等工序,同時面臨規模化量產的系統性問題。公司在業內率先突破圓柱全極耳電池製造工藝技術難題,開發出圓柱全極耳電芯裝配系列設備,產線效率、良品率更高,且擁有更加完善的專利佈局,並獲得第三方權威機構認可,技術水平行業領先。2020年至2022年,公司已累計向寧德時代、國軒高科、億緯鋰能等行業知名客户交付31 條圓柱全極耳電芯自動裝配線及多台圓柱全極耳電芯裝配專機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.